Validation of the test set in a cohort of patients with head and neck and gastric cancers from the KEYNOTE-028 trial showed a correlation with response to PD-1 therapy, with a deviation of <5% in anti-PD-1 response predictor score [68, 69]. This evidence concerns the gene PDCD1 and gastric cancer.